文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

细胞宿主反应脓毒症检测用于急诊科患者风险分层:一项汇总分析

Cellular host response sepsis test for risk stratification of patients in the emergency department: A pooled analysis.
PubMed 文献 · Acad Emerg Med · 2024-04-21
一句话结论在急诊有感染征象的成人中,细胞宿主反应检测(IntelliSep)可区分脓毒症高风险(特异性>83%)与低风险(敏感性>92%,脓毒症相关死亡率0%),并分层30天院内死亡率(p<0.001)、住院时长(p<0.01)和资源使用(p<0.001)。

该汇总分析纳入美国7个地理分布不同站点、5个成人(≥18岁)队列中经结构化盲法裁定且独立裁定小组与站点医生对Sepsis-3脓毒症和Sepsis-2严重脓毒症判定一致的高置信度患者(n=1002)。在有感染征象或怀疑感染的患者中,IntelliSep检测识别脓毒症高风险者的特异性>83%,与其他指标相似或更优;识别低风险者的敏感性>92%,脓毒症相关死亡率为0%,显著优于其他指标。该检测还能分层病情严重程度:30天院内死亡率p<0.001、住院时长p<0.01、医院资源使用p<0.001。作者认为,该检测为高风险和低风险患者提供临床可操作的结果,为有感染征象的患者提供快速、客观的风险分层手段;若整合入标准诊疗,可能有助于改善结局并减少不必要的抗生素使用。

要点

  • 在急诊有感染征象或怀疑感染的成人(≥18岁)中,IntelliSep细胞宿主反应检测识别脓毒症高风险者的特异性>83%,识别低风险者的敏感性>92%,低风险组脓毒症相关死亡率为0%。
  • 该检测可分层病情严重程度:30天院内死亡率p<0.001、住院时长p<0.01、医院资源使用p<0.001。
  • 汇总分析纳入5个成人队列、美国7个地理分布不同站点,仅纳入独立裁定小组与站点医生对Sepsis-3脓毒症和Sepsis-2严重脓毒症判定一致的高置信度患者(n=1002)。
  • 作者认为,该检测为有感染征象的患者提供快速、客观的风险分层;若整合入标准诊疗,可能有助于改善结局并减少不必要的抗生素使用。

适用人群与场景

  • 美国7个地理分布不同站点、5个成人(≥18岁)队列中,有感染征象或怀疑感染、且经结构化盲法裁定为高置信度标签的急诊患者(n=1002)。
  • 高置信度标签定义为独立裁定小组与站点级医生对Sepsis-3脓毒症和Sepsis-2严重脓毒症的判定均一致。

诊断标准与关键阈值

  • 脓毒症判定采用Sepsis-3定义,严重脓毒症判定采用Sepsis-2定义,由独立裁定小组与站点级医生分别判定并需一致。
  • 仅纳入对裁定标签高置信度的患者(n=1002)。

研究设计与关键结果

  • 研究类型:对5个成人(≥18岁)队列的汇总分析,队列来自美国7个地理分布不同站点,各队列为独立研究;仅纳入独立裁定小组与站点级医生对Sepsis-3脓毒症和Sepsis-2严重脓毒症判定一致的高置信度患者(n=1002)。
  • 在有感染征象或怀疑感染的患者中,IntelliSep检测识别脓毒症高风险者的特异性>83%,与其他指标相似或更优;识别低风险者的敏感性>92%,显著优于其他指标,低风险组脓毒症相关死亡率为0%。
  • 该检测可分层病情严重程度:30天院内死亡率p<0.001、住院时长p<0.01、医院资源使用p<0.001。

证据类型、等级与局限

  • 证据类型:对5个成人队列的汇总分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该检测为脓毒症高风险和低风险患者提供临床可操作的结果,为有感染征象的患者提供快速、客观的风险分层手段。
  • 作者认为,若将检测整合入标准诊疗,可能有助于改善结局并减少不必要的抗生素使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Sepsis is one of the most common, costly, and misdiagnosed conditions in U.S. emergency departments (EDs). ED providers often treat on nonspecific signs, subjective suspicion, or presumption of infection, resulting in over- and undertreatment. An increased understanding of host response has opened a new direction for sepsis diagnostics. The IntelliSep test is a U.S. Food and Drug Administration-cleared cellular host response diagnostic that could help distinguish sepsis in ED settings. Our objective was to evaluate the potential of the cellular host response test to expedite appropriate care for patients who present with signs of infection.

METHODS: We performed a pooled analysis of five adult (≥18 years) cohorts enrolled at seven geographically diverse U.S. sites in separate studies. Structured blinded adjudication was used to classify presence or absence of sepsis, and only patients with high confidence in the adjudicated label were included (n = 1002), defined as patients for whom there was consensus in the determination of sepsis per the Sepsis-3 and severe sepsis per the Sepsis-2 definitions between both the independent adjudication panel and the site-level physician.

RESULTS: Among patients with signs or suspicion of infection, the test achieved similar or better performance compared to other indicators in identifying patients at high risk for sepsis (specificity > 83%) and significantly superior performance in identifying those at low risk (sensitivity > 92%; 0% sepsis-associated mortality). The test also stratified severity of illness, as shown by 30-day in-hospital mortality (p < 0.001), hospital length of stay (p < 0.01), and use of hospital resources (p < 0.001).

CONCLUSIONS: Our data suggest that the cellular host response test provides clinically actionable results for patients at both high and low risk for sepsis and provides a rapid, objective means for risk stratification of patients with signs of infection. If integrated into standard of care, the test may help improve outcomes and reduce unnecessary antibiotic use.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. O'Neal HR, Sheybani R, Kraus CK, et al. Cellular host response sepsis test for risk stratification of patients in the emergency department: A pooled analysis. Acad Emerg Med. 2024. PMID: 38643433. doi:10.1111/acem.14923

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。